Literature DB >> 10566616

The effects of vasodilating drugs on pH in tumors.

E Adachi1, I F Tannock.   

Abstract

Hydralazine has been used widely to reduce tumor blood flow and thereby to induce hypoxia and to reduce extracellular pH (pHe) in tumors. Here we have investigated and compared the effects of the vasodilating drugs hydralazine, captopril, nifedipine, prazosin, sodium nitroprusside, and labetalol to reduce pHe in EMT-6 and KHT tumors of mice and to cause antitumor effects. After a single injection, captopril was most effective in reducing pHe in EMT-6 tumors with a decrease in mean pHe from 6.93 to 6.67 at 2 h after injection, while nifedipine was most effective for KHT tumors with a decrease in mean pHe from 6.96 to 6.75 at 1 h after injection. During 72 h of chronic administration into mice bearing tumors, nifedipine was ineffective in reducing pHe, but both captopril and hydralazine caused a small but significant reduction of pHe. Captopril caused significant delay in growth of the tumors, but had only a small effect on clonogenic cell survival. Captopril appears to be the most effective vasodilating drug to enhance tumor acidity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566616

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  3 in total

Review 1.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

2.  Acidic extracellular microenvironment and cancer.

Authors:  Yasumasa Kato; Shigeyuki Ozawa; Chihiro Miyamoto; Yojiro Maehata; Atsuko Suzuki; Toyonobu Maeda; Yuh Baba
Journal:  Cancer Cell Int       Date:  2013-09-03       Impact factor: 5.722

3.  Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.

Authors:  Kate M Bailey; Heather H Cornnell; Arig Ibrahim-Hashim; Jonathan W Wojtkowiak; Charles P Hart; Xiaomeng Zhang; Rafael Leos; Gary V Martinez; Amanda F Baker; Robert J Gillies
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.